Skip to main content
OpenTrials
Completed

NCT Number: NCT04796090

Genital Wart and Sexuality in Adolescence

The adolescence is a landmark in perceiving the sexuality and awareness about the sexual experiences. Genitals warts were shown to be a potential risk to impair the sexual functions in women. Adolescence is a vulnerable period in which the individuals may be prone to the negative effects of the disorders affecting sexual functions such as genital warts. The current study aimed to investigate the impact of genital warts on sexual functions in female adolescents.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Adolescent Development Communicable Diseases Condylomata Acuminata DNA Virus Infections Disease Attributes Genital Diseases Genital Wart Infections Papillomavirus Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Sexual Disorder, Physiological Sexual Dysfunction Sexual Dysfunction, Physiological Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Skin Diseases Skin Diseases, Infectious Skin Diseases, Viral Skin and Connective Tissue Diseases Tumor Virus Infections Urogenital Diseases Virus Diseases Warts

Age range

17 year–21 year

Sex eligibility

Female

Study type

Observational

Primary location

Ankara City Hospital

Ankara, 06100, Turkey (Türkiye)

About this study

This current study aimed to elucidate the impact of genital warts on female sexual function in adolescence. The current study also targeted to reveal whether there is any correlation between the genital warts and the female sexual dysfunction, as well as the sexuality related distress. The current study is conducted at Youth Center Outpatient Clinic of Ankara City Hospital which is a high-volume tertiary health care center in Turkey. The study was prospectively designed and data were collected between the 1 August 2020 and 1 February 2021. Totally 90 female adolescents between the age of 17-21 who had regular sexual intercourse with heterosexual partners were included. The Study group composed of 45 adolescents who had genital warts and the Control group included 45 healthy adolescents. Female sexual function Index (FSFI), Arizona Sexual Experiences Scale (ASEX) and Female Sexual Dysfunction Scale (FSDS) scores were compared between the two groups to evaluate the sexual functions. Difference between two independent means (two groups) power analysis demonstrated that this study achieved a power of 0.99, 0.98 , 0.99 with a 5% level of significance for comparison of 45 adolescents with genital warts and 45 healthy adolescents in terms of FSFI, ASEX, and FSDS scores, respectively.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The Study group included adolescents who was diagnosed as positive for genital warts during the examination.
  • The Control group was composed of healthy adolescents who admitted for contraceptive counselling.

Exclusion criteria

  • Chronical disease including rheumatological diseases, renal failure, diabetes mellitus, hypertension, dyslipidemia, obesity, thyroid dysfunction, cardiopulmonary diseases, malignancy, cerebrovascular diseases, psychiatric and mental disorders, cerebrovascular diseases, inflammatory bowel diseases.
  • Drug administration which may interfere sexual function.
  • Surgical intervention to genital organs.
  • History of pregnancy, delivery, and/or breastfeeding.

Treatment and study plan

Clinical Assessment

Other

FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.

Primary outcomes

  1. Female Sexual Function Index

    Time frame: Through study completion, an average of 6 months

    Questionnaire score with minimum and maximum levels of 2.4 and 36 points,respectively. Higher scores mean a better outcome.

Secondary outcomes

  1. Arizona Sexual Experiences Scale

    Time frame: Through study completion, an average of 6 months

    Questionnaire score with minimum and maximum levels of 5 and 30 points,respectively. Higher scores mean a worse outcome.

  2. Female Sexual Distress Scale-Revised

    Time frame: Through study completion, an average of 6 months

    Questionnaire score with minimum and maximum levels of 0 and 50 points,respectively. Higher scores mean a worse outcome.

Sponsors and collaborators

Lead sponsor

Ankara City Hospital Bilkent

Other

Registry information

Official study title

Genital Warts is Related With Sexual Dysfunction and Sexual Distress in Adolescence

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 12, 2021
Registry last updated
Mar 15, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.